Ora

FACT SHEET

*Inspiring the Future of Ophthalmic Clinical Development*

# OraNet™

## Building global relationships to enhance clinical success

OraNet™ is Ora's global family of research sites, dedicated to optimizing site preparedness, study execution, and data quality across all therapeutic areas of ophthalmology. Comprised of a strategic site community and a tailored site-support platform, OraNet™ turbocharges study startup timelines, accelerates enrollment, and empowers sponsors to complete their global studies on-time and within budget.

With access to Ora's validated clinical models and scales, OraNet™ can effectively standardize study environments to reduce data variability and increase the likelihood of study success. OraNet™ provides sites the power of global experience and the precision of local execution.

### Strategic Site Community

OraNet™ has strategic relationships with high-quality sites across the US, Europe, Latin America, and Asia — each one carefully selected for its strict adherence to rigorous standards in ophthalmic clinical trial conduct.

- Supported over 1000 individual ophthalmic sites across the globe, covering Anterior Segment, Retina, as well as Medical Devices.
- Results in a clinical trial that is more likely to finish on-time, within budget, and with high quality data that has minimal variability.
- Allows a sponsor to expedite feasibility, avoid competing trials, turbocharge study start-up timelines, and have access for study site activities in real-time — saving time and money.



### Forming Global Relationships

OraNet™ adapts our site-enablement approach to fit regional regulations & research cultures to provide a truly global solution.

- Individually support our sites in the US, Europe, & Asia with regional support teams who are embedded in the localized communities and understand the nuances of each area.
- Expedited contracting through our global site alliances can streamline start-up, even in challenging regulatory environments.
- Cross-train our world-wide clinical sites to maximize consistency across countries in global studies.

  *For example:* Ora's US clinical team traveled to China to train on technical procedures and oversee early study visit conduct to ensure consistency between the regions.

- Ongoing global expansion, including strategic relationships with sites in over 20 countries.

## Tailored Site Support Platform

OraNet™ offers industry-leading site support, including 90+ experienced Clinical Research Coordinators (CRCs) that enable our sites to focus on what they do best, while we take care of the rest.

- Embedded & Reserve Study Coordinators on-call to support sites in their clinics.
- Full study visit enablement with CRCs, including conduct support for block enrollment implementation.

  *For example:* OraNet™ has provided as many as 15 CRCs to a single site to support patient visits.

- On-site recruitment support, including patient chart evaluation, EMR review, & scheduling.
- Study database management & trained data-entry technicians.
- Highly skilled in-clinic team members to support sites with technical tasks such as imaging, phlebotomy, tear collection, and others.



## Feasibility, Site Selection, & Protocol Training

OraNet™ allows our sponsors to accelerate study start-up timelines by leveraging our site relationships to expedite feasibility, site-selection, and kickstart protocol training.

- Strategically select the right sites that are not over-utilized on competing trials.
- Leverage historical performance information and pre-collected feasibility of our sites to evaluate their capacity for each study protocol.
- OraNet™ sites are extensively trained and supported by our in-house clinical trial specialists who work closely with each site to instruct investigators and staff before the start of each new protocol.
- Collaborate with our sites to ensure efficient and consistent execution across the entire study timeline, ensuring strict protocol adherence.

## Block Enrollment

OraNet™ sites are further supported via our Block Enrollment offering, which involves concentrating clinical trial visits into a condensed window of time.

- Results in a higher volume of patients per site, thus requiring the involvement of fewer sites, leading to higher quality data with less variability.
- Block enrolled trials average 35% faster timelines than traditionally enrolled trials.
- Support our block-enrolling sites with investigator-delegated, fully-trained Clinical Research Coordinators (CRCs) to assist with the large volume of patients.
- CRCs perform a variety of tasks such as ICF, Medical History, BCVA, Study Drug Dispensation, Imaging/Photography, and are experts on Ora's models and scales.
- Patient volume is dependent on protocol design, with 20-40 patients commonly seen on site per day.
- Advanced scheduling gives sites full flexibility to accommodate their weekly practice schedules or to schedule solely on weekends.

**Advantages of patient-centricity**

- OraNet™ further supports our sites by collaborating with sub-specialty patient panels, support groups, and patient-focused organizations across the globe.
- OraNet™ partners with these groups to more closely understand the patient journey, optimize patient facing material, gain insights to the protocol perception, and make improvements to overall study design.
- The result of this patient insight shows up in OraNet's collaborative efforts with patient recruitment to enhance patient enrollment, engagement, and retention.
- OraNet™ aims to nurture and develop Ora's premier ophthalmic site network with enhanced focus on diverse, under-represented patient populations.

## In Summary

OraNet's strong site relationships allow our sponsors to take the path of least resistance along the journey to study completion. Together, we can bring more ophthalmic treatments to market for those in need, faster.

**Mike Watson**
Vice President OraNet™

As Vice President of OraNet™, Mike oversees Ora's entire global research site community. With over 14 years of experience in clinical research, Mike's understanding of how sites operate puts him in a unique position to drive Ora's strategy around site-enablement solutions.

> **"At Ora, we pride ourselves on enhancing clinical success, and consistently work towards our mission to be the CRO that sites want to work with."**

Prior to leading OraNet™, Mike held the position of Senior Director of Clinical Operations for Ora's Anterior Segment Division. Mike led trial strategy for the department and oversaw execution of over 80 Phase 1 through 4 clinical trials. In this role, Mike also led Ora's site development effort, resulting in the establishment of over 40 strategic relationships with ophthalmic sites. With Mike's leadership, these Ora-enabled sites later proved to outperform standard sites by up to 300%. It was this site enablement solution that led to the birth of OraNet™.

> **“It’s all about the relationships.”**

Since taking the role of Vice President in early 2021, Mike has further developed the OraNet™ global research site community in both Anterior and Posterior segments. Under Mike’s leadership, the site development team has doubled the size of OraNet’s retina-focused strategic site partners. Additionally, Mike is devoted to collaborating with his team to continually advance Ora’s global strategy, further enabling sites to perform at their best.

> **“OraNet™ is interested in research partners that want to do research for the right reasons — sites that are dedicated to serving their patient communities, and have an appetite for conducting research with operational excellence & scientific rigor.”**

## Mike has three goals for OraNet™ as we move into 2023 and beyond:

1. Support global practices with customized research-enablement solutions to achieve optimal in-clinic recruitment & operational success.
2. Empower practices to discover their study “sweet spot” by connecting the right sites with the right study opportunities, ensuring stable & synergistic growth.
3. Nurture and develop Ora’s premier ophthalmic site network, with enhanced focus on diverse, under-represented practices & patient populations.

# 100%
# Ophthalmology

# 100%
# Patient-focused

Ora

Ora is a global full-service ophthalmic drug and device development firm with vast capabilities through all steps of clinical research, including preclinical, clinical, CMC & regulatory, and patient and site evaluations. Through Ora's 40+ years of experience, the company has assisted in bringing more than 80 products to market. Ora's team of experts utilizes global regulatory strategies, integrated research operations, and extensive site and patient engagement to accelerate product development in anterior and posterior segment, as well as ophthalmic devices.